<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2025-25-48-53</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4694</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>К вопросу о применении психобиотиков в гастроэнтерологии и клинической медицине (научный обзор)</article-title><trans-title-group xml:lang="en"><trans-title>On the use of psychobiotics in gastroenterology and clinical medicine (scientific review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2164-3537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скворцов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Skvortsov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скворцов Всеволод Владимирович, д. м. н., доцент, проф. кафедры пропедевтики внутренних болезней</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Skvortsov Vsevolod V., DM Sci (habil.), associate professor, professor at Dept of Propaedeutics of Internal Diseases</p><p>Volgograd</p></bio><email xlink:type="simple">vskvortsov1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6725-8290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левитан</surname><given-names>Б. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Levitan</surname><given-names>B. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левитан Болеслав Наумович, д. м. н., проф., проф. кафедры факультетской терапии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Levitan Boleslav N., DM Sci (habil.), professor, professor at Dept of Faculty Therapy</p><p>Astrakhan</p></bio><email xlink:type="simple">bolev@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4130-058X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Касьянова</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasyanova</surname><given-names>T. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Касьянова Татьяна Рудольфовна, д. м.н, проф, зав. кафедрой факультетской терапии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Kasyanova Tatiana R., DM Sci (habil.), professor, head of Dept of Faculty Therapy</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-7525-4773</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чурюмов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Churyumov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чурюмов Александр Алексеевич, студент лечебного факультета</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Churyumov Alexander A., student at the Faculty of Medicine</p><p>Volgograd</p></bio><email xlink:type="simple">vita.medicus12@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-8077-0270</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкашина</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkashina</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черкашина Ксения Александрова, студентка педиатрического факультета</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Cherkashina Ksenia A., student at the Pediatric Faculty</p><p>Volgograd</p></bio><email xlink:type="simple">ksusha.cherk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-9238-111X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андрющенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Andryushchenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрющенко Амина Андреевна, студентка лечебного факультета</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Andryushchenko Amina A., student at the Faculty of Medicine</p><p>Volgograd</p></bio><email xlink:type="simple">aminaandrushenko2018@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical Unuversity</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Астраханский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Astrakhan State Medical Unuversity</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2025</year></pub-date><volume>0</volume><issue>25</issue><issue-title>«Гастроэнтерология и диетология» (3)</issue-title><fpage>48</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Скворцов В.В., Левитан Б.Н., Касьянова Т.Р., Чурюмов А.А., Черкашина К.А., Андрющенко А.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Скворцов В.В., Левитан Б.Н., Касьянова Т.Р., Чурюмов А.А., Черкашина К.А., Андрющенко А.А.</copyright-holder><copyright-holder xml:lang="en">Skvortsov V.V., Levitan B.N., Kasyanova T.R., Churyumov A.A., Cherkashina K.A., Andryushchenko A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4694">https://www.med-alphabet.com/jour/article/view/4694</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. В настоящее время пристальное внимание исследователей привлечено к изучению состояния и терапевтического значения кишечной микробиоты (КМ) человека, дисбаланс которой может приводить к возникновению или усугублению течения имеющихся заболеваний и синдромов.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Cистематизировать данные литературы о КМ и ее патогенетическом значении для человека, возможностях использования пробиотиков-психобиотиков в общеклинической практике и при некоторых гастроэнтерологических заболеваниях.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Основу исследований составили публикации отечественных и зарубежных авторов, доступные в специализированных базах данных (PubMed, Scopus, eLibrary). Выполнен анализ оригинальных и обзорных статей, метаанализов и клинических случаев по данной проблеме.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Кишечная микрофлора выполняет ряд важных для организма функций: пищеварительная, барьерная, метаболическая, иммунная, регуляторная (настроение, уровень стресса и тревоги). Кишечник постоянно получает регуляторные сигналы от центральной нервной системы (ЦНС) и, наоборот, на основе чего возник термин «ось кишечник-мозг», который включает в себя афферентные и эфферентные нервные, эндокринные, иммунологические и пищевые связи между ЖКТ и ЦНС, при нарушении которых возникают расстройства многих систем. Пробиотики-психобиотики, содержащие лактобактерии, были связаны с уменьшением боли в животе, показателями метеоризма и качеством жизни, в то время как Bifidobacterium улучшал императивные позывы и общие симптомы СРК. В другом исследовании пробиотик-психобиотик на основе Bifidobacterium longum NCC 3001 привел к снижению показателей депрессии и уменьшению реакции в миндалевидном теле и лобно-лимбической областях.</p></sec><sec><title>Заключение</title><p>Заключение. Использование психобиотиков в качестве дополнительного, а иногда и альтернативного метода лечения гастроэнтерологических заболеваний, таких как синдром раздраженного кишечника и ожирениe, показывает существенные положительные эффекты, особенно при присоединении к основному заболеванию депрессивного синдрома.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Currently, considerable attention of researchers is attracted to the study of the state and therapeutic significance of the human gut microbiota (GM), the imbalance of which can lead to the occurrence or aggravation of existing diseases and syndromes.</p></sec><sec><title>The purpose of the study</title><p>The purpose of the study. To systematize the literature data on GM and its pathogenetic significance for humans, the possibilities of using probiotics – psychobiotics in general clinical practice and in some gastroenterological diseases.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The research was based on publications by domestic and foreign authors, available in specialized databases (PubMed, Scopus, eLibrary). An analysis of original and review articles, meta-analyses, and clinical cases on this issue has been performed.</p></sec><sec><title>Results and discussions</title><p>Results and discussions. The gut microflora performs a number of important functions for the body: digestive, barrier, metabolic, immune, regulatory (mood, stress and anxiety levels). The intestine constantly receives regulatory signals from the central nervous system and vice versa, on the basis of which the term «enterocerebral axis» arose, which includes afferent and efferent nervous, endocrine, immunological and nutritional connections between the gastrointestinal tract and the central nervous system, which cause disorders of many systems. Probiotics-рsychobiotics containing lactobacilli-have been associated with reduced abdominal pain, flatulence, and quality of life, while Bifidobacterium improved imperative urges and general symptoms of IBS. In another study, a probiotic psychobiotic based on Bifidobacterium longum NCC 3001 led to a decrease in depression rates and a decrease in reactions in the amygdala and frontolimbic regions.</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of psychobiotics as an additional, and sometimes alternative, treatment method for gastroenterological diseases such as irritable bowel syndrome and obesity shows significant positive effects, especially when associated with the underlying disease of depressive syndrome.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>психобиотики</kwd><kwd>кишечная микробиота</kwd><kwd>ось кишечник-мозг</kwd><kwd>синдром раздраженного кишечника</kwd><kwd>ожирение</kwd><kwd>пробиотики</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psychobiotics</kwd><kwd>gut microbiota</kwd><kwd>gut-brain axis</kwd><kwd>irritable bowel syndrome</kwd><kwd>obesity</kwd><kwd>probiotics</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Michels N., Zouiouich S., Vanderbauwhede B. et al. Human microbiome and metabolic health: An overview of systematic reviews. Obes Rev. 2022; 23 (4): e13409. https://doi.org:10.1111/obr.13409</mixed-citation><mixed-citation xml:lang="en">Michels N., Zouiouich S., Vanderbauwhede B. et al. Human microbiome and metabolic health: An overview of systematic reviews. Obes Rev. 2022; 23 (4): e13409. https://doi.org:10.1111/obr.13409</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aggarwal N., Kitano S., Puah G. R.Y. et al. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chem Rev. 2023; 123 (1): 31–72. https://doi.org:10.1021/acs.chemrev.2c00431</mixed-citation><mixed-citation xml:lang="en">Aggarwal N., Kitano S., Puah G. R.Y. et al. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chem Rev. 2023; 123 (1): 31–72. https://doi.org:10.1021/acs.chemrev.2c00431</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mamieva, Z., Poluektova, E., Svistushkin V. et al. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations. World J Gastroenterol. 2022; 28 (12): 12041219. https://doi.org:10.3748/wjg.v28.i12.1204</mixed-citation><mixed-citation xml:lang="en">Mamieva, Z., Poluektova, E., Svistushkin V. et al. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations. World J Gastroenterol. 2022; 28 (12): 12041219. https://doi.org:10.3748/wjg.v28.i12.1204</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кляритская И. Л., Мошко Ю. А., Кривой В. В. и др. Современные представления о синдроме избыточного бактериального роста. Крымский терапевтический журнал. 2021; 2: 39–50.</mixed-citation><mixed-citation xml:lang="en">Kliaritskaia I. L., Moshko Y. A., Kryvy V. V. et al. Current understanding of bacterial overgrowth syndrome. Crimean Therapeutic J. 2021; 2: 39–50. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Гавриленко Д. И., Силивончик Н. Н. Транслокация кишечной микрофлоры при циррозе печени: механизм, клиническое значение, маркеры. Клиническая микробиология и антимикробная химиотерапия. 2021; 23 (2): 147–160. https://doi.org:10.36488/cmac.2021.2.147–160</mixed-citation><mixed-citation xml:lang="en">Gavrilenko D. I., Silivontchik N. N. Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance and markers. Clinical microbiology and antimicrobial therapy. 2021; 23 (2): 147–160. (In Russ.). https://doi.org:10.36488/cmac.2021.2.147-160</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McDonnell L, Gilkes A, Ashworth M, et al. Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis. Gut Microbes. 2021; 13 (1): 1–18. https://doi.org:10.1080/19490976.2020.1870402</mixed-citation><mixed-citation xml:lang="en">McDonnell L, Gilkes A, Ashworth M, et al. Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis. Gut Microbes. 2021; 13 (1): 1–18. https://doi.org:10.1080/19490976.2020.1870402</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karakan T., Ozkul C., Küpeli A. E. et al. Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders. Nutrients. 2021; 13 (2): 389. https://doi.org:10.3390/nu13020389</mixed-citation><mixed-citation xml:lang="en">Karakan T., Ozkul C., Küpeli A. E. et al. Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders. Nutrients. 2021; 13 (2): 389. https://doi.org:10.3390/nu13020389</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Margolis K. G., Cryan J. F., Mayer E. A. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021; 160 (5): 1486–1501. https://doi.org:10.1053/j.gastro.2020.10.066</mixed-citation><mixed-citation xml:lang="en">Margolis K. G., Cryan J. F., Mayer E. A. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021; 160 (5): 1486–1501. https://doi.org:10.1053/j.gastro.2020.10.066</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yi D. Y., Kim S. Y. Human Breast Milk Composition and Function in Human Health: From Nutritional Components to Microbiome and MicroRNAs. Nutrients. 2021; 13 (9): 3094. https://doi.org:10.3390/nu13093094</mixed-citation><mixed-citation xml:lang="en">Yi D. Y., Kim S. Y. Human Breast Milk Composition and Function in Human Health: From Nutritional Components to Microbiome and MicroRNAs. Nutrients. 2021; 13 (9): 3094. https://doi.org:10.3390/nu13093094</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Беляева И. А., Намазова-Баранова Л.С., Бомбардирова Е. П. и др. Последствия антибиотикотерапии в перинатальном периоде для кишечной микробиоты ребенка раннего возраста. Вопросы современной педиатрии. 2024; 23 (6): 447–455. https://doi.org/10.15690/vsp.v23i6.2822.</mixed-citation><mixed-citation xml:lang="en">Belyaeva I. A., Namazova-Baranova L.S., Bombardirova E. P. et al. Outcomes of Antibiotic Therapy During Perinatal Period for the Early Age Child’s Intestinal Microbiota. Voprosy sovremennoi pediatrii – Current Pediatrics. 2024;23(6):447–455. (In Russ.). https://doi.org:10.15690/vsp.v23i6.2822</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Джапаридзе Л. А., Солдатова О. А. Формирование микробиоты детей: ее роль в общем метаболизме. Журнал инфектологии. 2022; 14 (1): 20–30. https://doi.org/10.22625/2072-6732-2022-14-1-20-30</mixed-citation><mixed-citation xml:lang="en">Dzhaparidzе L. A., Soldatova O. A. Formation of the children microbiota: its role in overall metabolism. Journal Infectology. 2022; 14 (1): 20–30. (In Russ.). https://doi.org:0.22625/2072-6732-2022-14-1-20-30</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gomaa E. Z. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020; 113 (12): 2019–2040. https://doi.org:10.1007/s10482-020-01474-7</mixed-citation><mixed-citation xml:lang="en">Gomaa E. Z. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020; 113 (12): 2019–2040. https://doi.org:10.1007/s10482-020-01474-7</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cocean A. M., Vodnar D. C. Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health. Prog Neuropsychopharmacol Biol Psychiatry. 2024; 134: 111073. https://doi.org:10.1016/j.pnpbp.2024.111073</mixed-citation><mixed-citation xml:lang="en">Cocean A. M., Vodnar D. C. Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health. Prog Neuropsychopharmacol Biol Psychiatry. 2024; 134: 111073. https://doi.org:10.1016/j.pnpbp.2024.111073</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mosquera F. E.C., Lizcano M. S, Liscano Y. Effectiveness of Psychobiotics in the Treatment of Psychiatric and Cognitive Disorders: A Systematic Review of Randomized Clinical Trials. Nutrients. 2024; 16 (9): 1352. https://doi.org:10.3390/nu16091352</mixed-citation><mixed-citation xml:lang="en">Mosquera F. E.C., Lizcano M. S, Liscano Y. Effectiveness of Psychobiotics in the Treatment of Psychiatric and Cognitive Disorders: A Systematic Review of Randomized Clinical Trials. Nutrients. 2024; 16 (9): 1352. https://doi.org:10.3390/nu16091352</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dziedzic A., Maciak K., Bliźniewska-Kowalska K. et al. The Power of Psychobiotics in Depression: A Modern Approach through the Microbiota-Gut-Brain Axis: A Literature Review. Nutrients. 2024; 16 (7): 1054. https://doi.org:10.3390/nu16071054</mixed-citation><mixed-citation xml:lang="en">Dziedzic A., Maciak K., Bliźniewska-Kowalska K. et al. The Power of Psychobiotics in Depression: A Modern Approach through the Microbiota-Gut-Brain Axis: A Literature Review. Nutrients. 2024; 16 (7): 1054. https://doi.org:10.3390/nu16071054</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Binda S, Tremblay A., Iqbal U. H. et al. Psychobiotics and the Microbiota-Gut-Brain Axis: Where Do We Go from Here? Microorganisms. 2024; 12 (4): 634. https://doi.org:10.3390/microorganisms12040634</mixed-citation><mixed-citation xml:lang="en">Binda S, Tremblay A., Iqbal U. H. et al. Psychobiotics and the Microbiota-Gut-Brain Axis: Where Do We Go from Here? Microorganisms. 2024; 12 (4): 634. https://doi.org:10.3390/microorganisms12040634</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ross K. Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review. Explore (NY). 2023; 19 (5): 669–680. https://doi.org:10.1016/j.explore.2023.02.007</mixed-citation><mixed-citation xml:lang="en">Ross K. Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review. Explore (NY). 2023; 19 (5): 669–680. https://doi.org:10.1016/j.explore.2023.02.007</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bleibel L., Dziomba S., Waleron K. F. et al. Deciphering psychobiotics' mechanism of action: bacterial extracellular vesicles in the spotlight. Front Microbiol. 2023; 14: 1211447. DOI: 10.3389/fmicb.2023.1211447</mixed-citation><mixed-citation xml:lang="en">Bleibel L., Dziomba S., Waleron K. F. et al. Deciphering psychobiotics' mechanism of action: bacterial extracellular vesicles in the spotlight. Front Microbiol. 2023; 14: 1211447. DOI: 10.3389/fmicb.2023.1211447</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Del Toro-Barbosa M., Hurtado-Romero A., Garcia-Amezquita L.E., García-Cayuela T. Psychobiotics: Mechanisms of Action, Evaluation Methods and Effectiveness in Applications with Food Products. Nutrients. 2020; 12 (12): 3896. https://doi.org:10.3390/nu12123896</mixed-citation><mixed-citation xml:lang="en">Del Toro-Barbosa M., Hurtado-Romero A., Garcia-Amezquita L.E., García-Cayuela T. Psychobiotics: Mechanisms of Action, Evaluation Methods and Effectiveness in Applications with Food Products. Nutrients. 2020; 12 (12): 3896. https://doi.org:10.3390/nu12123896</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Андреева И. В., Толпыго А. В., Андреев В. А. и др. Психобиотики: новое направление в психофармакологии, или как бактерии влияют на наш мозг? Клиническая микробиология и антимикробная химиотерапия. 2022; 24 (2): 108–133. https://doi.org:10.36488/cmac.2022.2.108–133</mixed-citation><mixed-citation xml:lang="en">Аndreeva I. V., Tolpygo A. V., Andreev V. A. et al. Psychobiotics: a new way in psychopharmacology, or How do bacteria manage our brain? Clinical microbiology and antimicrobial therapy. (In Russ.). https://doi.org:10.36488/cmac.2022.2.108–133</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shaaban S. Y., El Gendy Y. G., Mehanna N. S. et al. The role of probiotics in children with autism spectrum disorder: a prospective, open-label study. Nutr Neurosci. 2018; 21 (9): 676–681. https://doi.org:10.1080/1028415X.2017.1347746</mixed-citation><mixed-citation xml:lang="en">Shaaban S. Y., El Gendy Y. G., Mehanna N. S. et al. The role of probiotics in children with autism spectrum disorder: a prospective, open-label study. Nutr Neurosci. 2018; 21 (9): 676–681. https://doi.org:10.1080/1028415X.2017.1347746</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Roman P., Carrillo-Trabalón F., Sánchez-Labraca N. et al. Are probiotic treatments useful on fibromyalgia syndrome or chronic fatigue syndrome patients? A systematic review. Benef Microbes. 2018; 9 (4): 603–611. https://doi.org:10.3920/BM2017.0125</mixed-citation><mixed-citation xml:lang="en">Roman P., Carrillo-Trabalón F., Sánchez-Labraca N. et al. Are probiotic treatments useful on fibromyalgia syndrome or chronic fatigue syndrome patients? A systematic review. Benef Microbes. 2018; 9 (4): 603–611. https://doi.org:10.3920/BM2017.0125</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kim C. S., Cha L., Sim M., Jung S. et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. 2021; 76 (1): 32–40. https://doi.org:10.1093/gerona/glaa090</mixed-citation><mixed-citation xml:lang="en">Kim C. S., Cha L., Sim M., Jung S. et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. 2021; 76 (1): 32–40. https://doi.org:10.1093/gerona/glaa090</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Black C. J., Ford A. C.. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020; 17: 473–486. https://doi.org:10.1038/s41575-020-0286-8</mixed-citation><mixed-citation xml:lang="en">Black C. J., Ford A. C.. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020; 17: 473–486. https://doi.org:10.1038/s41575-020-0286-8</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hendrix J., Ranginani D., Montero A. M. et al. Early adverse life events and post-traumatic stress disorder in patients with constipation and suspected disordered defecation. Neurogastroenterol Motil. 2022; 34 (3): e14195. https://doi.org/10.1111/nmo.14195</mixed-citation><mixed-citation xml:lang="en">Hendrix J., Ranginani D., Montero A. M. et al. Early adverse life events and post-traumatic stress disorder in patients with constipation and suspected disordered defecation. Neurogastroenterol Motil. 2022; 34 (3): e14195. https://doi.org/10.1111/nmo.14195</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Thijssen A. Y., Mujagic Z., Jonkers D. M. et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016; 43 (2): 272–282. https://doi.org:10.1111/apt.13459</mixed-citation><mixed-citation xml:lang="en">Thijssen A. Y., Mujagic Z., Jonkers D. M. et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016; 43 (2): 272–282. https://doi.org:10.1111/apt.13459</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chong P. P., Chin V. K., Looi C. Y. et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol. 2019; 10: 1136. DOI: 10.3389/fmicb.2019.01136</mixed-citation><mixed-citation xml:lang="en">Chong P. P., Chin V. K., Looi C. Y. et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol. 2019; 10: 1136. DOI: 10.3389/fmicb.2019.01136</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Zhang L., Wang X. et al. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin Gastroenterol Hepatol. 2016; 14 (11): 1602–1611.e5. https://doi.org:10.1016/j.cgh.2016.05.033</mixed-citation><mixed-citation xml:lang="en">Liu Y., Zhang L., Wang X. et al. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin Gastroenterol Hepatol. 2016; 14 (11): 1602–1611.e5. https://doi.org:10.1016/j.cgh.2016.05.033</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Peter J., Fournier C., Durdevic M. et al. A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. Psychosom Med. 2018; 80 (8): 698–709. https://doi.org:10.1097/PSY.0000000000000630</mixed-citation><mixed-citation xml:lang="en">Peter J., Fournier C., Durdevic M. et al. A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. Psychosom Med. 2018; 80 (8): 698–709. https://doi.org:10.1097/PSY.0000000000000630</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto-Sanchez M.I., Hall G. B., Ghajar K. et al. Probiotic Bifidobacterium longum NCC 3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017; 153 (2): 448–459.e8. https://doi.org:10.1053/j.gastro.2017.05.003</mixed-citation><mixed-citation xml:lang="en">Pinto-Sanchez M.I., Hall G. B., Ghajar K. et al. Probiotic Bifidobacterium longum NCC 3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017; 153 (2): 448–459.e8. https://doi.org:10.1053/j.gastro.2017.05.003</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Didari T., Mozaffari S., Nikfar S., Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015; 21 (10): 3072–3084. https://doi.org:10.3748/wjg.v21.i10.3072</mixed-citation><mixed-citation xml:lang="en">Didari T., Mozaffari S., Nikfar S., Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015; 21 (10): 3072–3084. https://doi.org:10.3748/wjg.v21.i10.3072</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Левитан Б. Н., Скворцов В. В., Самохвалова П. Д. Современные подходы в лечении хеликобактериоза у больных язвенной болезнью. Медицинский алфавит. 2021; (40): 7–13. https: //doi.org/10.33667/2078-5631-2021-40-7-13</mixed-citation><mixed-citation xml:lang="en">Levitan B. N., Skvortsov V. V., Samokhvalova P. D. Modern approaches in treatment of helicobacteriosis in patients with peptic ulcer. Medical alphabet. 2021; (40): 7–13. (In Russ.). https: //doi.org/10.33667/2078-5631-2021-40-7-13</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Asha M. Z., Khalil S. F. H. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ Med J. 2020; 20 (1): e13–e24. https://doi.org:10.18295/squmj.2020.20.01.003</mixed-citation><mixed-citation xml:lang="en">Asha M. Z., Khalil S. F. H. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ Med J. 2020; 20 (1): e13–e24. https://doi.org:10.18295/squmj.2020.20.01.003</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Li L., Guo C. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016; 16 (1): 62. https://doi.org:10.1186/s12876–016–0470-z</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Li L., Guo C. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016; 16 (1): 62. https://doi.org:10.1186/s12876–016–0470-z</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Субботина Т. И., Коростелева О. Г., Ищук Ю. В. и др. Психобиотики в функциональном питании: роль и возможности применения. Ульяновский медико-биологический журнал. 2025; 1: 20–32. https://doi.org:10.34014/2227-1848-2025-1-20-32</mixed-citation><mixed-citation xml:lang="en">Subbotina T. I., Korosteleva O. G., Ishchuk Yu. V. Psychobiotics in functional nutrition – the role and application possibilities. Ulyanovsk Medical and Biological Journal. 2025; 1: 20–32. (In Russ.). https://doi.org:10.34014/2227-1848-2025-1-20-32</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Florêncio G. P., Xavier A. R., Natal A. C.C. et al. Synergistic Effects of Probiotics and Lifestyle Interventions on Intestinal Microbiota Composition and Clinical Outcomes in Obese Adults. Metabolites. 2025; 15 (2): 70. https://doi.org:10.3390/metabo15020070</mixed-citation><mixed-citation xml:lang="en">Florêncio G. P., Xavier A. R., Natal A. C.C. et al. Synergistic Effects of Probiotics and Lifestyle Interventions on Intestinal Microbiota Composition and Clinical Outcomes in Obese Adults. Metabolites. 2025; 15 (2): 70. https://doi.org:10.3390/metabo15020070</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.</mixed-citation><mixed-citation xml:lang="en">World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
